News on companion diagnostics and drug/test co-development.
HTG terminated a companion diagnostic development deal with Qiagen in the wake of that company's discontinuation of next-generation sequencing instruments.
The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.
Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.
The company has signed technology deals with Repertoire Genesis of Japan, Stratifyer Molecular Pathology of Germany, and the University of Bonn.
Newly appointed interim CEO Thierry Bernard attempted to assuage investors' fears in the wake of a tumultuous month for Qiagen.
